Module-based Enzyme-Immuno-Assay (ELISA) for the confirmation of samples positive for IgG and IgM antibodies to COVID-19 in first screening. The test is particularly useful in monitoring patients, infected by COVID-19, from the time of symptoms offset up to full recovery.
The test can be used in addition to identify (a) the specificity (“typing”) of antibodies to the major immunodominant COVID-19 antigens and (b) identify those samples with a titer of “potentially” neutralizing IgG to Spike antigens such to select the donor as a candidate for immunotherapy, as well.